Science 37 Holdings, Inc. (NASDAQ: SNCE - Get Rating) was the recipient of a significant drop in short-term interest rates during the month of May. As of May 15, there was a short interest of a total of 892,100 shares, which is a decrease of 34.9% compared to April 30, a total of 1,370,000 shares. Currently, 1.1% of the company’s shares are sold briefly. Based on an average trading volume of 278,300 shares, the ratio of days to coverage is currently 3.2 days.
Institutional investors have recently modified their ownership of the business. Citigroup Inc. bought a new stake in Science 37 in the 1st quarter worth $ 37,000. Virtu Financial LLC bought a new position in shares of Science 37 during the 1st quarter worth about $ 60,000. JPMorgan Chase & Co. raised its stake in Science 37 shares by 29.0% during the 1st quarter. JPMorgan Chase & Co. now owns 14,574 shares of the company worth $ 78,000 after buying an additional 3,272 shares during the period. Penserra Capital Management LLC bought a new position in shares of Science 37 during the 4th quarter worth about $ 92,000. Finally, Shai Capital LLC bought a new position in shares of Science 37 during the 1st quarter worth about $ 120,000. 46.12% of the shares are owned by hedge funds and other institutional investors.
SNCE has been the subject of numerous research reports. Robert V. Baird reiterated the “buy” rating and announced a target price of $ 12.00 for shares of Science 37 in a research note on Friday, April 8. Zacks Investment Research downgraded Science 37 from a “buy” rating to a “hold” rating in a report on Friday. One researcher-analyst rated the shares with a rating of retention, and four gave a rating of buying shares of the company. Based on data from MarketBeat.com, stocks currently have an average “Buy” rating and consensus target price of $ 12.38.
Whether you want to learn the basics of futures or are an experienced veterinarian who wants to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today’s futures markets!
SNCE opened for $ 3.68 on Friday. The business has a 50-day moving average cost of $ 4.17 and a moving 200-day moving average of $ 7.67. Science 37 has a twelve-month low of $ 2.75 and a high of $ 15.10.
Science 37 (NASDAQ: SNCE - Get Rating) last released its earnings results on Tuesday, March 22nd. The company reported ($ 0.29) earnings per share (EPS) for the quarter. The company had revenue of $ 20.38 million for the quarter, compared to analysts’ estimates of $ 15.02 million. Stock analysts expect Science 37 to earn -0.45 earnings per share for the current year.
About science 37 (Get a rating)
Science 37 Holdings, Inc. is developing a technology platform that enables agile clinical trials and specialized networks to orchestrate the conduct of trials. The company is developing an agile operating system for clinical trials that enables modern and digital approaches to clinical research by bringing together all parties, including patient and trial researchers, nurses, coordinators, and sponsors? to enable workflow, centralized evidence generation, and data reconciliation.
See also
This current news release is generated by narrative scientific technology and financial data from MarketBeat to provide readers with the fastest and most accurate reporting. The MarketBeat editorial team reviewed this story before it was published. Send any questions or comments about this story to [email protected]
Do you need to invest $ 1,000 in Science 37 now?
Before you think about Science 37, you want to hear this.
MarketBeat monitors the best rated and most successful Wall Street analysts and the actions they recommend to their clients on a daily basis. MarketBeat has identified five stocks that top analysts are quietly whispering to their customers to buy now before the wider market catches on … and Science 37 was not on the list.
While Science 37 currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better purchases.
See 5 actions here